| Line Item | 2025-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.8M | — | +31.1% |
| Cost of Revenue | $8.3M | — | +48.6% |
| R&D Expense | $5.6M | — | +34.1% |
| SG&A Expense | $7.9M | — | -33.1% |
| Operating Income | -$11.1M | — | +20.4% |
| Pre-tax Income | -$11.3M | — | +17.5% |
| Income Tax | $0 | — | -100.0% |
| Net Income | -$11.3M | — | +17.5% |
| EPS (Basic) | -$0.07 | — | +22.2% |
| EPS (Diluted) | -$0.07 | — | +22.2% |
| Line Item | 2025-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $58.7M | -16.4% | -45.9% |
| Accounts Receivable | $12.5M | +27.0% | +60.5% |
| Inventory | $19.4M | +35.3% | +85.8% |
| Current Assets | $111.6M | -14.2% | -45.0% |
| Total Assets | $174.1M | -11.3% | -33.9% |
| Current Liabilities | $47.8M |
| Line Item | 2025-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.1M | — | +67.4% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | -$935K | — | -102.1% |
| Financing Cash Flow | -$223K | — | — |
| Free Cash Flow | -$10.1M | — | +67.4% |
| -37.5% |
| Long-term Debt | $5.6M | -3.7% | — |
| Total Liabilities | $74.0M | -13.2% | -30.2% |
| Stockholders' Equity | $100.2M | -9.9% | -36.4% |